Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alina Dulau

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Seminars in Oncology|December 18, 2017
Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironmentLekha Mikkilineni, Diana Whitaker-Menezes, Marina Domingo-Vidal, et al.
Clinical Immunology (Orlando, Fla.)|May 10, 2019
Heterozygous activating mutation in RAC2 causes infantile-onset combined immunodeficiency with susceptibility to viral infectionsSvetlana O Sharapova, Emma Haapaniemi, Inga S Sakovich, et al.
Pediatric Blood & Cancer|January 26, 2020
Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvementHaneen Shalabi, Constance M Yuan, Amita Kulshreshtha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2020
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell LeukemiaDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
Leukemia|July 27, 2022
Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemiaEmma M Groarke, Bhavisha A Patel, Ruba Shalhoub, et al.
Journal for Immunotherapy of Cancer|June 9, 2023
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicityJennifer Jess, Bonnie Yates, Alina Dulau-Florea, et al.
Blood Advances|October 4, 2021
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variantDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
The Oncologist|February 8, 2021
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple MyelomaDickran Kazandjian, Alexander Dew, Elizabeth Hill, et al.
Blood Advances|August 24, 2021
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1Ifeyinwa Emmanuela Obiorah, Bhavisha A Patel, Emma M Groarke, et al.
The Journal of Infectious Diseases|January 20, 2021
Lost in Translation: Lack of CD4 Expression due to a Novel Genetic DefectAndrea Lisco, Peying Ye, Chun-Shu Wong, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Seminars in Oncology|December 18, 2017
Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironmentLekha Mikkilineni, Diana Whitaker-Menezes, Marina Domingo-Vidal, et al.
Clinical Immunology (Orlando, Fla.)|May 10, 2019
Heterozygous activating mutation in RAC2 causes infantile-onset combined immunodeficiency with susceptibility to viral infectionsSvetlana O Sharapova, Emma Haapaniemi, Inga S Sakovich, et al.
Pediatric Blood & Cancer|January 26, 2020
Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvementHaneen Shalabi, Constance M Yuan, Amita Kulshreshtha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2020
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell LeukemiaDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
Leukemia|July 27, 2022
Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemiaEmma M Groarke, Bhavisha A Patel, Ruba Shalhoub, et al.
Journal for Immunotherapy of Cancer|June 9, 2023
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicityJennifer Jess, Bonnie Yates, Alina Dulau-Florea, et al.
Blood Advances|October 4, 2021
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variantDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
The Oncologist|February 8, 2021
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple MyelomaDickran Kazandjian, Alexander Dew, Elizabeth Hill, et al.
Blood Advances|August 24, 2021
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1Ifeyinwa Emmanuela Obiorah, Bhavisha A Patel, Emma M Groarke, et al.
The Journal of Infectious Diseases|January 20, 2021
Lost in Translation: Lack of CD4 Expression due to a Novel Genetic DefectAndrea Lisco, Peying Ye, Chun-Shu Wong, et al.
Pageof 4